Literature DB >> 19590432

Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.

Giulia Morsica1, Sabrina Bagaglio, Paola Cicconi, Maria R Capobianchi, Giampietro Pellizzer, Pietro Caramello, Anna Orani, Cristina Moioli, Giuliano Rizzardini, Caterina Uberti-Foppa, Massimo Puoti, Antonella D'Arminio Monforte.   

Abstract

OBJECTIVE: To investigate the reciprocal inhibitory effects of hepatitis B virus (HBV)/hepatitis C virus (HCV)/hepatitis D virus (HDV) infections in naive and previously antiretroviral-experienced HIV-positive patients.
DESIGN: This retrospective study involved 72 consecutive patients of the Italian Cohort Naive Antiretroviral cohort: 21 coinfected with HBV/HCV (group 1BC), 18 infected with HBV (group 2B), and 33 infected with HCV (group 3C).
METHODS: Viral interference between HBV and HCV was assessed by means of the qualitative detection, quantification, and genotyping of each virus; HDV infection was assessed by means of genomic amplification.
RESULTS: Univariate analysis showed that HBV DNA was less frequently detected in group 1BC than in group 2B (16 of 21 vs 18 of 18; P = 0.02), their HBV load was significantly lower (median 3.9 vs 5.4 log10 HBV DNA copies/mL; P = 0.002), and they more frequently carried HBV genotype D (12 of 13 vs 4 of 11; P = 0.0071). HCV RNA was less frequently detected in group 1BC than in group 3C (12 of 21 vs 33 of 33; P < 0.0001), and HDV RNA was more frequently detected in group 1BC than in group 2B (9 of 21 vs 2 of 18; P = 0.028). Multivariate analysis of the HBV-infected subjects showed that the risk of HCV coinfection was associated with older age [relative risk 0.28, 95% confidence interval (CI): 0.09 to 0.90; P = 0.033 for every 10 years older] and intravenous drug use (relative risk 73, 95% CI: 2.4 to >999.999; P = 0.013). The only predictor of HBV coinfection in HCV-infected individuals was a lower HCV load (relative risk 0.30, 95% CI: 0.11 to 0.79 for every additional log10 HCV RNA; P = 0.015).
CONCLUSION: HBV and HCV showed alternative dominant replication in the I.Co.N.A. cohort, with HBV having a more unfavorable effect on HCV replication.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590432     DOI: 10.1097/QAI.0b013e3181add592

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  5 in total

1.  Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption.

Authors:  S Bagaglio; L Porrino; A Lazzarin; G Morsica
Journal:  Infection       Date:  2010-06-09       Impact factor: 3.553

2.  Longitudinal evaluation of occult hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption.

Authors:  S Bagaglio; G Bianchi; A Danise; L Porrino; C Uberti-Foppa; A Lazzarin; A Castagna; G Morsica
Journal:  Infection       Date:  2011-03-22       Impact factor: 3.553

3.  Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis.

Authors:  Mamta K Jain; Emmanuel Seremba; Rafia Bhore; Doan Dao; Reeti Joshi; Nahid Attar; He-Jun Yuan; William M Lee
Journal:  AIDS Patient Care STDS       Date:  2012-01-12       Impact factor: 5.078

4.  Hepatic decompensation in patients with HIV/Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) triple infection versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide therapy.

Authors:  Vincent Lo Re; Li Wang; Scott Devine; Onur Baser; Temitope Olufade
Journal:  Clin Infect Dis       Date:  2014-06-18       Impact factor: 9.079

5.  The Prevalence and Risk Factors of Hepatitis Delta Virus in HIV/HBV Co-Infected Patients in Shiraz, Iran, 2012.

Authors:  Mohammad Motamedifar; Mohammad Taheri; Kamran Bagheri Lankarani; Mina Gholami; Mahmood Amini Lari; Hossein Faramarzi; Jamal Sarvari
Journal:  Iran J Med Sci       Date:  2015-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.